Evaluation of a new lipophilic prodrug 3', 5'-dioctanoyl-5-bromodeoxyuridine (BrdU-C8) suspended in Lipiodol as a radiosensitizer for the treatment of AH136B tumor.
The effect of anti-cancer treatment on the AH136B tumor was studied using external beam irradiation in combination with a new oil-soluble agent, 3', 5'-dioctanoyl-5-bromodeoxyuridine (BrdU-C8), a lipophilic prodrug of BrdU. BrdU-C8 was dissolved in an oily lymphographic agent, Lipiodol (BrdU-C8/Lipiodol). BrdU-C8/Lipiodol is selectively accumulated in the neovasculature of the tumor and gradually releases BrdU. The AH136B tumor cell, a transplantable rat ascites hepatoma cell line, was implanted in the dorsal foot of rats. In vivo labeling index (L.I.) of the tumor cells after the intraarterial infusion of BrdU-C8/Lipiodol was significantly increased compared to the L.I. observed after intraarterial or intravenous infusion of BrdU. In addition, X-ray irradiation in combination with intraarterial infusion of BrdU-C8/Lipiodol significantly inhibited the tumor growth, indicating the increased radiosensitizing effect.
Ohara
C
C
Department of Surgery II, Kumamoto University Medical School, Japan.
Beppu
T
T
Yamaguchi
Y
Y
Masuda
Y
Y
Fukushima
S
S
Kawaguchi
T
T
Ogawa
M
M
D000818:Animals; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007459:Iodized Oil / Q000008:administration & dosage; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000532:radiotherapy*; D011355:Prodrugs / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D011355:Prodrugs; D011838:Radiation-Sensitizing Agents; C081889:3',5'-dioctanoyl-5-bromodeoxyuridine; D007459:Iodized Oil; D001973:Bromodeoxyuridine